Genius Brands International Inc. (NASDAQ: GNUS) shares are 318.04% up in the year-to-date (YTD) period and have moved -3.39% or -$0.04 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +2,109.30% lower. Comparatively, the stock is -90.28% down YTD and -56.49% over the trailing 3-month period. If we look at the shorter duration, its week performance is -5.00% and -28.30% over the month.
1 analysts offering the recommendations for the stock have a consensus rating of 2.00 to suggest that the GNUS stock is a “Moderate Buy. 0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $1.14. The forecasts give the Genius Brands International Inc. stock a price target range of $4.50 on the higher side while at least one analyst think the stock could plunge to a low of $4.50. The two limits represent an upside potential of 74.67% or 74.67%.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 8 over the last 12 months, while SEC filings reveal that there have been 3 insider sales over the same period. Insiders have purchases 13,116,429 shares while those sold by company executives and officers stand at 908,603. The last 3 months have seen insiders trade a total of 12,111,429 and 908,603 in purchases and sales respectively.
KLEIN MICHAEL G, a Director at the company, bought 5,000 shares worth $13650.0 at $2.73 per share on Jun 26. The Director had earlier bought another 25,000 GNUS shares valued at $70750.0 on Jul 06. The shares were bought at $2.83 per share. Heyward Andy (Chief Executive Officer) sold 460,574 shares at $2.94 per share on Jun 19 for a total of $1.35 million while KLEIN MICHAEL G, (Director) bought 10,000 shares on Jun 18 for $27900.0 with each share fetching $2.79.
Heat Biologics Inc. (NASDAQ:HTBX), on the other hand, is trading around $1.34 with a market cap of $184.20M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting $Financial Services per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Heat Biologics Inc. (HTBX) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
HTBX’s operating expenses over the recent quarter were at -$4.84 million. This represented a 916.53% of the company’s total revenues which amounted $0.59 million. With this in place, we can see that the company’s diluted EPS declined -$0.05 on the year-over-year period, shrinking to -$0.14 as given in the last earnings report.
In terms of the balance sheet & cash flow as of Name, the total assets figure advanced to $58.15 million from $37.82 million over the previous quarter. Short term investments amounted to $26.31 million while total current assets were at $47.6 million. The cash flow from operating activities totaled -$10.07 million, significantly lower than the -$8.24 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$10.29 million.
Insiders have transacted a total of 2 times at Heat Biologics Inc. over the last 6 months, with insider purchases undertaken 1 times and accounting for 15,625 shares. Insider sales totaled 4,440 shares over the same period, with these deals completed in 1 transactions. Looking at these numbers, we realize that net purchases over that period are 0.0 shares. Insiders now hold a total of ProShares Short 7 10 Year Treas shares after the latest sales, with American Funds High-Income Trus net shares purchased.
Insiders own 6.04% of the company shares, while shares held by institutions stand at 13.00% with a share float percentage of 75.53M.